Kwong P. Lee

FDA investigator

Appears on 12 documents from 2015 to 2026, mostly at sites in New York. Most often cites design controls (21 CFR 820.30(c)).

12
Documents on file
3.2
Observations per 483
2015
First seen
2026
Most recent

What they cite most

From 38 observations

Activity by year

2015: 1, 2016: 1, 2019: 1, 2020: 3, 2021: 1, 2022: 2, 2023: 2, 2026: 1

Where

New York 9 · Connecticut 1 · Massachusetts 1 · New Jersey 1

Is Kwong P. Lee coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

12 documents, newest first
FirmOpen
483 Medivis, IncMar 3, 2026 · New York, New York
483 Form 483 · FEI 3017580485Jul 12, 2023 · Amherst, Massachusetts
483 Biodex Medical Systems, IncFeb 10, 2023 · Shirley, New York
483 HansBiomed USA, IncNov 8, 2022 · Englewood Cliffs, New Jersey
483 Perrigo New York, Inc.Oct 24, 2022 · Bronx, New York
483 Koios Medical, IncMay 13, 2021 · New York, New York
483 Advanced Monitored Caregiving, IncNov 12, 2020 · New York, New York

About this profile

What does Kwong P. Lee inspect?

Kwong P. Lee appears on 12 documents on file covering 11 sites, mostly in New York.

What do they cite most often?

21 CFR 820.30(c) (design controls), followed by 21 CFR 803.17 and 21 CFR 820.198(a).

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Kwong P. Lee is dated Mar 3, 2026.